Single-dose, live-attenuated Japanese encephalitis vaccine in children aged 12-18 months: randomized, controlled phase 3 immunogenicity and safety trial.
about
Japanese encephalitis: the virus and vaccinesPersistence of Wild-Type Japanese Encephalitis Virus Strains Cross-Neutralization 5 Years After JE-CV ImmunizationImmune response to live-attenuated Japanese encephalitis vaccine (JE-CV) neutralizes Japanese encephalitis virus isolates from south-east Asia and India.Immunogenicity and safety of currently available Japanese encephalitis vaccines: a systematic reviewComparing the immunogenicity and safety of 3 Japanese encephalitis vaccines in Asia-Pacific area: A systematic review and meta-analysis.Control of Japanese encephalitis in Asia: the time is nowA randomized study of the immunogenicity and safety of Japanese encephalitis chimeric virus vaccine (JE-CV) in comparison with SA14-14-2 vaccine in children in the Republic of KoreaMemory immune response and safety of a booster dose of Japanese encephalitis chimeric virus vaccine (JE-CV) in JE-CV-primed childrenPlaque reduction neutralization antibody test does not accurately predict protection against dengue infection in Ratchaburi cohort, Thailand.Safety and immunogenicity of a live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®) in children.Japanese encephalitis vaccines: Immunogenicity, protective efficacy, effectiveness, and impact on the burden of disease.Preparing children for international travel: need for training and pediatric-focused research.Japanese B Encephalitis: An Overview of the Disease and Use of Chimerivax-JE as a Preventative Vaccine.Five-Year Antibody Persistence Following a Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) Booster in JE-CV-Primed Children in the Philippines.
P2860
Q27010434-D128CB9D-AEDE-47BE-9575-D78BBC61F656Q33712740-380DA12D-DDC9-47B6-B439-681031A8A672Q35127585-301FF63B-4938-4AB5-A5AB-FD75C3C02E71Q35558900-65E98597-55C0-4C04-BAC7-9320C3D9E958Q35886942-DF1F4B1C-6450-4B4E-BE68-18A8F74AAD5AQ36125852-FEC8C307-04E0-4C26-AD0A-5BCE1B89D10EQ37159706-B5F968A0-D18A-43EA-B956-AAB591A3F9BEQ37521922-111B11E3-B4E2-4C53-BB2B-637CF8DD7137Q37683785-68B6A29B-50A6-488C-8D3F-3DC21D71985BQ38640233-234FCB16-E867-46D8-8FAF-11FA4B382AAFQ39181962-96A37BD0-E56C-4722-9BC0-F9DBC5B7F972Q40195150-DBECAB7D-59AB-49D5-99F7-5F6066E92572Q40196301-89AFADCD-1BCD-4F92-ADD7-87A209F8B160Q47555071-69270AAE-0E73-4B69-9AC4-96DBC11A0C1B
P2860
Single-dose, live-attenuated Japanese encephalitis vaccine in children aged 12-18 months: randomized, controlled phase 3 immunogenicity and safety trial.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Single-dose, live-attenuated J ...... munogenicity and safety trial.
@en
Single-dose, live-attenuated J ...... munogenicity and safety trial.
@nl
type
label
Single-dose, live-attenuated J ...... munogenicity and safety trial.
@en
Single-dose, live-attenuated J ...... munogenicity and safety trial.
@nl
prefLabel
Single-dose, live-attenuated J ...... munogenicity and safety trial.
@en
Single-dose, live-attenuated J ...... munogenicity and safety trial.
@nl
P2093
P2860
P921
P356
P1476
Single-dose, live-attenuated J ...... munogenicity and safety trial.
@en
P2093
Alain Bouckenooghe
Chitsanu Pancharoen
Emmanuel Feroldi
Kerdpanich Phirangkul
Maria R Capeding
Pope Kosalaraksa
Sophia Gailhardou
Veerachai Watanaveeradej
P2860
P304
P356
10.4161/HV.20071
P577
2012-07-01T00:00:00Z